Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06690957

Somatostatin Receptor PET/CT in SSTR-Related Disease Patients

Status
Recruiting
Phase
Study type
Observational
Enrollment
500 (estimated)
Sponsor
Tianjin Medical University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

To evaluate the potential usefulness of 68Ga/18F-TATE/JR11/LM3 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.

Detailed description

Subjects with various SSTR-related disease patients underwent 68Ga/18F-TATE/JR11/ LM3 PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-TATE/JR11/LM3 PET/CT were calculated.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TEST68Ga/18F-TATE/JR11/LM3Each subject receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3, and undergo PET/CT imaging within the specificed time.

Timeline

Start date
2019-02-01
Primary completion
2027-10-01
Completion
2027-10-01
First posted
2024-11-15
Last updated
2025-02-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06690957. Inclusion in this directory is not an endorsement.